CHEMDOODLE LICENSE OR EQUAL
ID: 75F40125Q00087Type: Combined Synopsis/Solicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFFOOD AND DRUG ADMINISTRATIONFDA OFFICE OF ACQ GRANT SVCSBeltsville, MD, 20705, USA

NAICS

Professional Organizations (813920)

PSC

IT AND TELECOM - DATA CENTER PRODUCTS (HARDWARE AND PERPETUAL LICENSE SOFTWARE) (7C20)

Set Aside

Total Small Business Set-Aside (FAR 19.5) (SBA)

Original Source

https://sam.gov/opp/acdc1a21dd4848b880d03eb0e0cc87e3/view
Timeline
  1. 1
    Posted Jan 10, 2025, 12:00 AM UTC
  2. 2
    Updated Jan 10, 2025, 12:00 AM UTC
  3. 3
    Due Jan 16, 2025, 4:00 AM UTC
Description

The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking quotes for a ChemDoodle site license or an equivalent chemical drawing tool through a Total Small Business Set-Aside procurement. The software must be compatible with Windows, Mac, and Linux operating systems and include features such as interactive drawing capabilities, various export and import formats, IUPAC naming functionalities, and integration with Excel for property calculations. This procurement is crucial for providing FDA users with the necessary tools for chemical structure representation and analysis, with the contract set to span from January 21, 2025, to January 20, 2026. Interested vendors should contact Tiffany Hatcher at Tiffany.Hatcher@fda.hhs.gov or call 240-402-1492 for further details.

Point(s) of Contact
Tiffany Hatcher
(240) 402-1492
Tiffany.Hatcher@fda.hhs.gov
Files
Title
Posted
RFQ 75F40125Q00087.pdf
Jan 10, 2025, 5:04 PM UTC
The U.S. Food and Drug Administration (FDA) is soliciting quotes for the ChemDoodle Advanced Software Suite, a chemical drawing tool, through a Total Small Business Set-Aside procurement. The software is intended for all FDA users and must be compatible with Windows, Mac, and Linux operating systems, including onsite maintenance and technical support. Key features required include interactive drawing capabilities, various export and import formats, IUPAC naming functionalities, and integration with Excel for calculating properties of chemical structures. The contract, which is firm-fixed price, spans one year from January 21, 2025, to January 20, 2026, with specific deliverables and maintenance provisions outlined. The FDA emphasizes that the contractor must provide essential support and access to updates during the contract period. The document details the inspection and acceptance criteria, performance evaluation processes, and compliance with electronic invoicing through the Department of Treasury’s Invoice Processing Platform, ensuring adherence to federal regulations and efficiency in payment processing.
Lifecycle
Title
Type
CHEMDOODLE LICENSE OR EQUAL
Currently viewing
Combined Synopsis/Solicitation
Similar Opportunities
Biorelevant characterization system for subcutaneous injections
Buyer not available
The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking vendors to provide a Biorelevant Characterization System for evaluating subcutaneous drug formulations. This system is intended to enhance the capabilities of the Center for Drug Evaluation and Research (CDER) by enabling the investigation of drug release performance under simulated physiological conditions, utilizing integrated sensors and automated operation for unattended assessments. The initiative underscores the FDA's commitment to ensuring the quality, safety, and efficacy of pharmaceutical products while promoting innovation and domestic manufacturing. Interested parties, particularly small businesses under NAICS Code 334516, are encouraged to submit their qualifications by contacting Erika Crawford at erika.crawford@fda.hhs.gov or Maria Finan at maria.finan@fda.hhs.gov, as this is a Sources Sought Notice for market research purposes only, with no contract to be awarded at this stage.
Drug Utilization: Hospital Inpatient & Emergency Dept. Data (Recompete)
Buyer not available
The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking proposals for a contract titled "Drug Utilization: Hospital Inpatient & Emergency Dept. Data (Recompete)." The primary objective of this procurement is to gain immediate and unlimited access to commercially available drug utilization data for both adult and pediatric populations in hospitals, which will support the FDA's regulatory activities related to drug safety and utilization assessments. This data is crucial for enhancing public health safety and informing regulatory decision-making regarding marketed drugs. Interested parties should note that the contract may cover up to $5 million over several years, with a response deadline of April 16, 2025. For further inquiries, potential offerors can contact Ryan Alexander at ryan.alexander@fda.hhs.gov.
GraphPad Prism Subscription Renewal
Buyer not available
The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to renew a contract for 500 subscriptions of GraphPad Prism software, which is critical for biostatistical analysis and scientific graphing. This non-competitive procurement is justified under the Federal Acquisition Regulation (FAR) due to GraphPad Software, LLC being the sole provider of the software, with the renewal period set from April 8, 2025, to April 7, 2026. GraphPad Prism is widely utilized by research institutions and pharmaceutical companies, ensuring the accuracy and efficiency of scientific data analysis within the NIH. Interested vendors may express their capabilities, but the government retains discretion over competitive offers, with the total contract value not exceeding $250,000. For inquiries, contact Verne L. Griffin at verne.griffin@nih.gov or 301-594-7730, or Michael L. Falzone at michael.falzone@nih.gov or 301-827-1873.
IDIQ for the purchase of human induced pluripotent stem cell-derived cells
Buyer not available
The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking to award a sole-source contract for the procurement of human induced pluripotent stem cell-derived cells from Fujifilm Cellular Dynamics. This acquisition aims to support a research program focused on microphysiological systems (MPS), which are critical for advanced in-vitro models used in drug safety and efficacy assessments. The cells, including cardiomyocytes, neurons, astrocytes, and hepatocytes, will be cryopreserved and utilized by FDA scientists at the Center for Drug Evaluation and Research, ensuring continuity in ongoing projects due to the established partnership with Fujifilm. Interested vendors may submit capability statements within 15 days of the notice, with the response deadline set for 10 AM EST on May 2, 2025; inquiries should be directed to Telisha Wilson at telisha.wilson@fda.hhs.gov.
Jefferson Laboratories On-Site Laboratory Equipment Maintenance, Repair, and Fabrication Services
Buyer not available
The U.S. Department of Health and Human Services, through the Food and Drug Administration (FDA), is seeking qualified vendors to provide on-site laboratory equipment maintenance, repair, and fabrication services at the National Center for Toxicological Research (NCTR) in Jefferson, Arkansas. The procurement aims to ensure the optimal performance of critical scientific instruments and equipment, which include balances, autoclaves, bioanalyzers, and more, while also offering specialized design and fabrication services for unique research projects. This opportunity is crucial for maintaining the functionality of NCTR's extensive research facilities, which support various scientific endeavors, including food safety and toxicological research. Interested vendors should note that the solicitation is expected to be released between April 9 and April 16, 2025, with a closing date 30 days after posting, and the anticipated award date is around June 21, 2025. For further inquiries, vendors can contact Suzanne Martella at suzanne.martella@fda.hhs.gov or by phone at 870-543-7540.
Purchase of Lab Supplies
Buyer not available
The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified vendors to provide various lab supplies, including cleaning and sanitation products, under solicitation number 75N98025Q00021. The procurement aims to ensure the NIH is equipped with essential supplies such as paper towels, disinfectant wipes, and hand soap, which are critical for maintaining hygiene and safety in healthcare environments. This opportunity includes a partial small business set-aside, encouraging participation from small businesses, including service-disabled veteran-owned and women-owned enterprises, with a focus on timely delivery within a 10-day timeframe. Interested vendors must submit their quotes via email by 4:30 PM Eastern Daylight Time on April 9, 2025, and can direct inquiries to Carol Hayden at haydenc@od.nih.gov.
Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Buyer not available
The Department of Defense (DoD) is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement (BPA) and the Uniform Formulary Additional Discount Program (ADP) through the Defense Health Agency (DHA). This procurement aims to establish agreements for pharmaceutical agents that will be included in the DoD's Uniform Formulary, which is essential for providing effective pharmacy benefits to military personnel and their families. The upcoming Pharmacy and Therapeutics (P&T) Committee meeting, scheduled for May 7-8, 2025, will review newly approved drugs, with quotes due by April 17, 2025. Interested manufacturers should contact Keith Marasigan at keith.b.marasigan2.ctr@health.mil or Stephanie Erpelding at stephanie.j.erpelding.civ@health.mil for further details and to ensure compliance with submission requirements.
Biostatistical Software
Buyer not available
The Department of Defense, through the Defense Health Agency (DHA), is conducting market research for biostatistical software solutions, specifically targeting Cytel’s East Horizon software and its associated modules. The objective is to identify commercial items that can fulfill specific biostatistical requirements essential for meeting FDA regulatory standards in medical research. This RFI is crucial for gathering insights into available software that supports various clinical trial designs and statistical analyses across the ORA portfolios. Interested vendors are encouraged to submit white papers by April 23, 2025, to Matthew Gembe at matthew.w.gembe.civ@health.mil, with all submissions treated as proprietary and not returned.
6505--Pharmaceutical - FdG/NaF
Buyer not available
The Department of Veterans Affairs is soliciting quotes for the supply of two radiopharmaceuticals, Sodium Fluoride and Fluorodeoxyglucose, intended for use at the Philadelphia VA Medical Center. This procurement aims to enhance patient care by ensuring the availability of essential medical supplies that are critical for imaging procedures and equipment testing. Interested vendors must comply with stringent regulatory requirements and are required to maintain adequate stock levels, provide timely deliveries, and ensure proper labeling and quality control. The solicitation, numbered 36C24425Q0532, will remain open until April 11, 2025, at 10:00 AM Eastern Time, and all inquiries should be directed in writing to Contract Specialist Matthew Wright at matthew.wright6@va.gov, as no phone inquiries will be accepted.
Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Buyer not available
The Department of Defense, through the Defense Health Agency, is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at establishing an effective pharmacy benefits program for the Military Health System. This procurement involves the evaluation and selection of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on newly approved drugs that will be reviewed by the Pharmacy and Therapeutics Committee in February 2025. Interested vendors must submit their pricing information, including National Drug Codes (NDCs), by December 19, 2024, and are encouraged to participate in a pre-quotation teleconference on December 4, 2024. For further inquiries, vendors can contact Tracy Banks at tracy.e.banks2.civ@mail.mil or Julia Trang at julia.n.trang.civ@health.mil.